Welcome to our dedicated page for Acadia Healthcare Company SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acadia Healthcare Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acadia Healthcare Company's regulatory disclosures and financial reporting.
Acadia Healthcare (ACHC) agreed to settle a previously disclosed securities case for $179 million, with no admission or finding of liability and subject to preliminary and final approval by the District Court. The Company plans to fund the payment from approximately $30 million in anticipated insurance proceeds, plus cash on hand and existing credit lines.
Acadia will record the aggregate settlement amount, less associated tax benefits, as an expense for the quarter ending December 31, 2025. Because the settlement funds will be excluded from adjusted EBITDA, the Company stated this has no impact on previously announced financial guidance. As of September 30, 2025, cash and cash equivalents were $118.7 million, availability under the $1.0 billion revolving credit facility was $786.7 million, and the Consolidated Total Net Leverage Ratio was 3.4x.
Acadia Healthcare (ACHC) reported Q3 2025 results with revenue of $851.6 million, up from $815.6 million a year ago. Net income attributable to the company was $36.2 million versus $68.1 million last year, and diluted EPS was $0.40 versus $0.74.
Year to date, operating cash flow reached $218.2 million. The company invested $478.6 million in capital expenditures and ended the quarter with cash of $118.7 million. Q3 “transaction, legal and other costs” were $42.9 million, including $38.7 million for government investigations. Payor mix remained weighted to Medicaid at 56.9% in the quarter.
Acadia refinanced its debt with a new Credit Facility comprising a $1.0 billion revolver and a $650.0 million term loan maturing in 2030, and issued $550.0 million of 7.375% Senior Notes due 2033, contributing to long‑term debt of $2.285 billion at quarter‑end. Under its $300.0 million share repurchase program authorized in 2025, the company bought back 1,706,625 shares for $50.4 million, leaving $250.0 million available.
Acadia Healthcare (ACHC) reported leadership changes and furnished quarterly results. The company announced that Chief Operating Officer Dr. Nasser Khan resigned effective November 3, 2025. Acadia entered a transition and separation agreement under which Dr. Khan will serve as executive advisor to the CEO through December 31, 2025 and receive a lump-sum payment of $515,000 no later than March 15, 2026. He remains eligible for a 2025 cash bonus based on actual performance as determined by the Board or its Compensation Committee.
Acadia has begun a search for a new COO, with Dr. Khan’s former responsibilities covered by other executive leaders in the interim. The company also furnished a press release with operating and financial results for the third quarter ended September 30, 2025 as an exhibit.
Acadia Healthcare (ACHC) reported an insider equity award for its Chief Financial Officer, Todd S. Young. On 10/27/2025, he acquired 48,445 shares of common stock at $0.00 per share. According to the filing, these shares will vest over three years in equal annual installments beginning 10/27/2026. Following this transaction, Young beneficially owned 48,445 shares, held directly.
Acadia Healthcare (ACHC): A Form 3 was filed for Chief Financial Officer Todd S. Young, reporting his initial beneficial ownership with the issuer. The filing states that no securities are beneficially owned.
The event date is 10/27/2025, and the Form 3 was signed by Brian Farley as attorney-in-fact on 10/28/2025 pursuant to an Exhibit 24 power of attorney.
Acadia Healthcare Company, Inc. disclosed an employment agreement for Todd Young dated October 7, 2025 that sets compensation and relocation terms for his role. The package includes a one-time $460,000 cash award payable by March 31, 2026 if he remains employed through that date, a one-time grant of time-based restricted stock units with a grant-date fair value of $1,200,000 that vest ratably over three years, and a minimum annual equity award for fiscal 2026 with grant-date fair value of at least $2,900,000. The agreement also provides eligibility for severance on certain terminations and reimbursement for reasonable relocation expenses to the greater Franklin, Tennessee area within 12 months of his start date.
The Vanguard Group reported owning 9,417,045 shares of Acadia Healthcare Company, Inc., representing 10.19% of the outstanding common stock as of 09/30/2025. Vanguard reports 0 shares of sole voting power, 598,737 shares of shared voting power, 8,718,595 shares of sole dispositive power, and 698,450 shares of shared dispositive power. The filing states these shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The reporting address is 100 Vanguard Blvd., Malvern, PA, and the filing is signed by Ashley Grim, Head of Global Fund Administration, on 10/06/2025.
Wellington Management and related entities report beneficial ownership of 9,423,548 shares of Acadia Healthcare Company, Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing is a Schedule 13G amendment listing four Wellington-related filers organized in Massachusetts and Delaware. The reported holdings show no sole voting or dispositive power and instead reflect shared voting power of 8,982,886 shares and shared dispositive power of 9,423,548 shares, indicating these securities are owned of record by Wellington clients and managed by its investment advisers. The filing names one client exceeding a 5% threshold: the Vanguard Health Care Fund. Signatures are provided by a Wellington regulatory analyst on 10/07/2025.
Insider sale reported: Nasser Khan, listed as Chief Operating Officer and reporting person for Acadia Healthcare Company, Inc. (ACHC), disposed of 973 shares of common stock on 09/30/2025 at a reported price of $24.54 per share. After the transaction he beneficially owned 55,023 shares in a direct ownership form. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Khrom-affiliated investors disclosed a meaningful 5.5% stake in Acadia Healthcare (ACHC), holding 5,037,448 shares directly through Khrom Investments and 5,044,376 shares when including Eric Khrom's direct holdings. The group acquired the shares in open-market purchases for an aggregate purchase price of approximately $132.89 million using working capital, and the shares are held in margin accounts. The filing states the investors believe ACHC is undervalued and that they have engaged, and intend to continue engaging, with the company’s management and board about strategic options to maximize shareholder value. The investors reserve the right to buy or sell additional securities, pursue derivative or hedging transactions, and potentially propose changes to operations, board composition, capital structure or other strategic actions.